# US 2002/0160981 A1 · Compositions containing an association of aspirin and an anti-Xz oligosaccharide and use of an anti-Xa oligosaccharide optionally in combination with aspirin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0160981 A1
- Document ID: US20020160981A1
- Status: Published application
- Kind: A1
- Application number: 10/155,221
- Filed: 2002-05-28
- Published: 2002-10-31
- Earliest claimed: 1997-03-14
- Assignees: Sanofi-Synthelabo
- Inventors: Roger Guilcaume Cariou; Jacobus Christianus Johannes Stiekema
- Web page: https://patentgrep.com/patent/US20020160981A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to the use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, alone or in association with aspirin, for the preparation of medicaments intended for preventing or treating thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty. The subject of the invention is moreover pharmaceutical compositions for the treatment or prophylaxy of thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin, optionally mixed with one or more pharmaceutically acceptable excipients.

## Claims

### Claim 1

Pharmaceutical composition for the treatment or prophylaxy of thromboembolic diseases in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin, optionally mixed with one or more pharmaceutically acceptable excipients.

### Claim 2 (depends on 1)

Composition according to claim 1, comprising from 5 to 30 mg of the said oligosaccharide and from 200 to 800 mg of aspirin.

### Claim 3 (depends on 1)

Composition according to claim 1, comprising from 8 to 20 mg of the said oligosaccharide and from 400 to 600 mg of aspirin.

### Claim 4 (depends on 1)

Composition according to claim 1, wherein the oligosaccharide is methyl O-(2-deoxy-2-sulphoamino-6-O-sulpho-α-D-gluco-pyranosyl) -(1→4)-O-(β-D-glucopyranosyluronic acid)-(1→4)-O-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2-O-sulpho-α-L-idopyranosyl-uronic acid)-(1→4)-2-deoxy-2-sulphoamino-6-O-sulpho-α-D-glucopyranoside, in which the anion has the structure (A)
4
or one of its pharmaceutically acceptable salts.

### Claim 5 (depends on 4)

Composition according to claim 4, wherein the oligosaccharide is the decasodium salt.

### Claim 6

Process for the treatment or prophylaxy of thromboembolic diseases in a mammal having undergone a percutaneous transluminal angioplasty comprising the administration, to the said mammal, of an effective quantity of at least one synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, alone or in combination with aspirin.

### Claim 7 (depends on 6)

Process according to claim 6, in which the oligosaccharide is methyl O-(2-deoxy-2-sulphoamino-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(β-D-glucopyrano-syluronic acid)-(1→4)-O-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2-O-sulpho-α-L-idopyranosyluronic acid)-(1→4)-2-deoxy-2-sulphoamino-6-O-sulpho-α-D-glucopyranoside, in which the anion has the structure (A)
5
or one of its pharmaceutically acceptable salts.

### Claim 8 (depends on 7)

Process according to claim 7, in which the oligosaccharide is the decasodium salt.

### Claim 9 (depends on 6)

Process according to claim 6, comprising the administration of 0.1 to 100 mg of oligosaccharide per day and per kilo of bodyweight of the mammal to be treated.

### Claim 10 (depends on 9)

Process according to claim 9, comprising, in addition, the administration of 0.1 to 100 mg of aspirin per day and per kilo of bodyweight of the mammal to be treated.

### Claim 11 (depends on 6)

Process according to claim 6, characterized in that the oligosaccharide is administered via the intravenous or subcutaneous route.
